First Time Loading...

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 38.64 USD 2.2% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. [ Read More ]

The intrinsic value of one HALO stock under the Base Case scenario is 54.76 USD. Compared to the current market price of 38.64 USD, Halozyme Therapeutics Inc is Undervalued by 29%.

Key Points:
HALO Intrinsic Value
Base Case
54.76 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Halozyme Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HALO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Halozyme Therapeutics Inc

Provide an overview of the primary business activities
of Halozyme Therapeutics Inc.

What unique competitive advantages
does Halozyme Therapeutics Inc hold over its rivals?

What risks and challenges
does Halozyme Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Halozyme Therapeutics Inc recently?

Summarize the latest earnings call
of Halozyme Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Halozyme Therapeutics Inc.

Provide P/S
for Halozyme Therapeutics Inc.

Provide P/E
for Halozyme Therapeutics Inc.

Provide P/OCF
for Halozyme Therapeutics Inc.

Provide P/FCFE
for Halozyme Therapeutics Inc.

Provide P/B
for Halozyme Therapeutics Inc.

Provide EV/S
for Halozyme Therapeutics Inc.

Provide EV/GP
for Halozyme Therapeutics Inc.

Provide EV/EBITDA
for Halozyme Therapeutics Inc.

Provide EV/EBIT
for Halozyme Therapeutics Inc.

Provide EV/OCF
for Halozyme Therapeutics Inc.

Provide EV/FCFF
for Halozyme Therapeutics Inc.

Provide EV/IC
for Halozyme Therapeutics Inc.

Show me price targets
for Halozyme Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Halozyme Therapeutics Inc?

How accurate were the past Revenue estimates
for Halozyme Therapeutics Inc?

What are the Net Income projections
for Halozyme Therapeutics Inc?

How accurate were the past Net Income estimates
for Halozyme Therapeutics Inc?

What are the EPS projections
for Halozyme Therapeutics Inc?

How accurate were the past EPS estimates
for Halozyme Therapeutics Inc?

What are the EBIT projections
for Halozyme Therapeutics Inc?

How accurate were the past EBIT estimates
for Halozyme Therapeutics Inc?

Compare the revenue forecasts
for Halozyme Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Halozyme Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Halozyme Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Halozyme Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Halozyme Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Halozyme Therapeutics Inc with its peers.

Analyze the financial leverage
of Halozyme Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Halozyme Therapeutics Inc.

Provide ROE
for Halozyme Therapeutics Inc.

Provide ROA
for Halozyme Therapeutics Inc.

Provide ROIC
for Halozyme Therapeutics Inc.

Provide ROCE
for Halozyme Therapeutics Inc.

Provide Gross Margin
for Halozyme Therapeutics Inc.

Provide Operating Margin
for Halozyme Therapeutics Inc.

Provide Net Margin
for Halozyme Therapeutics Inc.

Provide FCF Margin
for Halozyme Therapeutics Inc.

Show all solvency ratios
for Halozyme Therapeutics Inc.

Provide D/E Ratio
for Halozyme Therapeutics Inc.

Provide D/A Ratio
for Halozyme Therapeutics Inc.

Provide Interest Coverage Ratio
for Halozyme Therapeutics Inc.

Provide Altman Z-Score Ratio
for Halozyme Therapeutics Inc.

Provide Quick Ratio
for Halozyme Therapeutics Inc.

Provide Current Ratio
for Halozyme Therapeutics Inc.

Provide Cash Ratio
for Halozyme Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Halozyme Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Halozyme Therapeutics Inc?

What is the current Free Cash Flow
of Halozyme Therapeutics Inc?

Financials

Balance Sheet Decomposition
Halozyme Therapeutics Inc

Current Assets 746.4m
Cash & Short-Term Investments 336m
Receivables 234.2m
Other Current Assets 176.2m
Non-Current Assets 986.8m
PP&E 74.9m
Intangibles 889.7m
Other Non-Current Assets 22.2m
Current Liabilities 112.5m
Accounts Payable 11.8m
Accrued Liabilities 100.7m
Non-Current Liabilities 1.5B
Long-Term Debt 1.5B
Other Non-Current Liabilities 37.7m
Efficiency

Earnings Waterfall
Halozyme Therapeutics Inc

Revenue
829.3m USD
Cost of Revenue
-192.4m USD
Gross Profit
636.9m USD
Operating Expenses
-296.8m USD
Operating Income
340.1m USD
Other Expenses
-58.5m USD
Net Income
281.6m USD

Free Cash Flow Analysis
Halozyme Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

HALO Profitability Score
Profitability Due Diligence

Halozyme Therapeutics Inc's profitability score is 84/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
84/100
Profitability
Score

Halozyme Therapeutics Inc's profitability score is 84/100. The higher the profitability score, the more profitable the company is.

HALO Solvency Score
Solvency Due Diligence

Halozyme Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
High Altman Z-Score
Long-Term Solvency
60/100
Solvency
Score

Halozyme Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HALO Price Targets Summary
Halozyme Therapeutics Inc

Wall Street analysts forecast HALO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HALO is 52.13 USD with a low forecast of 39.39 USD and a high forecast of 75.6 USD.

Lowest
Price Target
39.39 USD
2% Upside
Average
Price Target
52.13 USD
35% Upside
Highest
Price Target
75.6 USD
96% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

HALO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HALO Price
Halozyme Therapeutics Inc

1M 1M
-4%
6M 6M
+10%
1Y 1Y
+14%
3Y 3Y
-17%
5Y 5Y
+140%
10Y 10Y
+402%
Annual Price Range
38.64
52w Low
30.28
52w High
44.03
Price Metrics
Average Annual Return 44.47%
Standard Deviation of Annual Returns 61.83%
Max Drawdown -49%
Shares Statistics
Market Capitalization 4.9B USD
Shares Outstanding 127 054 000
Percentage of Shares Shorted 8.4%

HALO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.9B USD

Dividend Yield

0%

Description

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. The company is headquartered in San Diego, California and currently employs 145 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The firm's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The firm's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The firm's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. The rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids, potentially reducing the treatment burden.

Contact

CALIFORNIA
San Diego
11388 Sorrento Valley Rd
+18587948889.0
https://www.halozyme.com/

IPO

2003-01-30

Employees

145

Officers

President, CEO & Director
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Senior VP & CFO
Ms. Nicole LaBrosse
Senior VP & Chief Technical Officer
Dr. Michael J. LaBarre Ph.D.
Senior VP & Chief Legal Officer
Mr. Mark Snyder Esq.
Chief Operations Officer
Ms. Cortney Caudill M.B.A.
Head of Investor Relations & Corporate Communications
Ms. Tram Bui
Show More
Chief Human Resources Officer
Ms. Amy Marinne Fox
Chief Medical Officer
Dr. Steve Knowles MBBS
Chief Manufacturing Officer & Head of Technical Operations
Dr. Christopher Bryant Ph.D.
Head of Quality
Ms. Kristin Schwartzbauer
Show Less

See Also

Discover More
What is the Intrinsic Value of one HALO stock?

The intrinsic value of one HALO stock under the Base Case scenario is 54.76 USD.

Is HALO stock undervalued or overvalued?

Compared to the current market price of 38.64 USD, Halozyme Therapeutics Inc is Undervalued by 29%.